The medical device industry, particularly in the fields of aesthetic surgery and metabolic health, is undergoing a rapid transformation. With rising global obesity rates, there is a growing demand for minimally invasive procedures and more cost-effective treatment options. Traditional bariatric surgeries like gastric bypass and lap band, though effective, carry significant surgical risks, long recovery times, and high costs, often deterring patients. Simultaneously, the highly competitive cosmetic surgery market faces its challenges in constantly improving procedural safety, surgical precision, and post-operative outcomes.
While Injectable glucagon-like peptide-1 (GLP-1) agonists now provide a viable alternative to surgical procedures, they are far from a perfect solution. They are a lifelong sentence to expensive, weekly injections. Serious side effects may occur, such as diabetic retinopathy, cholecystitis and gallstones, kidney problems, pancreatitis, increased risk of thyroid cancer, and hypoglycemia; but nausea, fatigue, and headache are the most common. 20-40% of the weight patients lose is muscle. At least 10 to15% of patients will not tolerate the drug or do not experience sufficient appetite suppression to lose significant weight. Early reports indicate that 35-50% of patients do not complete the first year taking the drug because of side effects, complications, or cost. After discontinuation, about 40% of patients regain weight, with about 20% regaining all the weight they lost and more.
Dr. Robert L. Cucin (M.D., J.D., M.B.A., F.A.C.S.), a board-certified plastic and reconstructive surgeon, has made it his mission to combat the global obesity epidemic by combining innovation and clinical insight. Leveraging his experience as a general and plastic surgeon and a serial inventor, including power-assisted liposuction, and licensor to major corporations such as Mentor and Ethicon, he founded BioSculpture Technology, Inc. to further the art of tissue sculpting with advanced solutions. Under his leadership, BioSculpture Technology is bridging the gap between cosmetic and clinical outcomes, offering a safer alternative path for those who need intervention but fear surgery and any downtime for recuperation.
Foundations rooted in Innovation and purpose
BioSculpture Tech is a spinoff of Rocin Laboratories, Inc., a Biomedical R&D firm founded by Dr. Cucin to advance innovations in biomedical dermatologicals and surgical devices. Biosculpture Tech was born out of the overwhelming success of the Lipotome® division that exclusively licensed liposuction-related patents. The idea was to fast-track the development and introduction of advanced surgical tools by licensing the parent company’s diversified tissue aspiration platform and patent portfolio.
However, Dr. Cucin’s vision for BioSculpture Tech extended far beyond commercial success. As a seasoned cosmetic surgeon, he views surgery as an art and believes that the right instruments can “Unleash the artist in the surgeon®.” This philosophy led to the development of tools that not only enhanced cosmetic procedures but also pioneered methods to safely remove visceral fat, the hidden culprit behind metabolic disorders. Over time, the company’s mission evolved into something far nobler – to combat the global obesity crisis with transformative, minimally invasive, and effective medical solutions.
Pioneering Minimally Invasive Fat Removal
BioSculpture Technology, Inc. is pioneering novel medical technologies that empower surgeons with minimally invasive tools to deliver better outcomes while reducing patient costs and recovery time. Founded in 2001, the company first gained traction with its patented Twin-Cannula Assisted Liposuction (TCAL) system, branded as the Airbrush Liposculpture® System II, which received FDA clearance. This device offers a unique balance of precision and safety in liposuction procedures, easing the physical burden on surgeons by automating the cannula’s back-and-forth motion.
Now, the company is advancing its most ambitious innovation: Endoscopic Visceral Lipectomy (EVL®). Unlike traditional bariatric surgeries, EVL is a minimally invasive technique designed to remove visceral fat, the root cause of obesity and related metabolic disorders. This breakthrough marks a significant leap in obesity treatment.
Both TCAL and EVL are underlined by BioSculpture Tech’s core mission, which is to democratize safe and permanent solutions for obesity, metabolic syndrome, and type 2 diabetes. By bridging the fields of elective cosmetic surgery and chronic disease management, the company positions itself at the forefront of a growing health crisis. With over 200 million Americans classified as obese or overweight, BioSculpture Technology’s solutions stand as a scalable response to one of the most urgent medical challenges of our time.
Redefining Obesity Treatment at Its Root
One of the biggest challenges to global metabolic health today is the relentless rise of obesity, the spiraling increased prevalence of obesity in each new generation “We are getting fatter and less healthy, and obesity-related diseases, including cancers, have tripled over the past two decades,” says Dr. Cucin. “This is bankrupting healthcare systems and diminishing both the lifespan and quality of life for over a third of the world’s population.” McKinsey estimates the cost of obesity-related disease expenditures will surge to $17 trillion by 2035, an alarming forecast demanding urgent innovation.
BioSculpture Tech’s response is its most ambitious innovation yet: Endoscopic Visceral Lipectomy (EVL®). Unlike traditional bariatric surgeries that bypass or shrink the stomach but leave visceral fat largely untouched, EVL® directly removes this deep abdominal fat, which is the root cause of insulin resistance, chronic inflammation, type 2 diabetes, and heart disease. By physically extracting this pathogenic fat, EVL® has the potential to reset metabolic rate, reduce ghrelin-driven hunger, and catalyze sustained fat loss.
The company’s approach is grounded in understanding the physiologic consequences of fat in different locations whether they drain into the portal or systemic circulation. Subcutaneous fat, often treated through liposuction, is primarily cosmetic. However, visceral fat, located within your abdomen under the abdominal muscles, drains into the liver and poses a far greater threat to health. EVL® will employ real-time cytokine analysis and imaging to identify and remove fat deposits that secrete high levels of resistin. Post-surgery, patients will be monitored via a dedicated app, refining outcomes through feedback loops.
R&D at the Frontline of Obesity Treatment
BioSculpture Tech is committed to equipping surgeons with innovations that fight obesity at its root, restore health with precision, and improve lives across generations. At the heart of this commitment lies a robust R&D engine powering its breakthroughs. “We’ve spent more than $1.3 million on R&D and plan to maintain it at 5% of sales,” says Dr. Cucin. This investment has led to significant advancements in their market-tested liposuction devices, including the shift from pneumatic to electromagnetic actuation. By replacing the pressurized gas with a concentric ramped coil design, these tools perform more efficiently and are accessible for the next generation of surgeons.
Their proprietary laparoscopic IP is made with advanced technologies such as stereoscopic imaging, AR vascular enhancement, and real-time tissue cytokine analysis, enabling safer and more targeted fat removal. Beyond technology, the firm values human feedback. They connect with both patients and surgeons in the post-operative period through open-ended questions and structured feedback to refine their offerings and deliver better outcomes.
Technology behind the Smart Surgical tools
As invested as BioSculpture Tech is in R&D, the company also keeps a mindful eye on relevant technologies. Dr. Robert Cucin emphasizes that AI, with its virtually limitless memory and rapid processing capabilities, is revolutionizing the way medicine understands disease. AI can analyse massive and complex datasets, such as pathology slides, MRIs, and mammograms, to identify subtle patterns and uncover new causative disease associations. This breakthrough will lead to the development of more targeted and personalized treatments.
In parallel, BioSculpture Tech is pioneering the use of advanced 3D printing and rapid prototyping to design, test, refine, and manufacture custom surgical instruments. Through iterative trial and error, BioSculpture Tech offers a suite of tools that enhance surgical reach and control, particularly in hard-to-access regions like the mesentery. As Dr. Cucin describes, these technologies unleash the artist in the surgeon® by removing the drudgery from repetitive and laborious procedures such as liposuction, add precision and control, and enable safe, laparoscopic minimally invasive mesenteric fat removal.
Non-Negotiable Quality
For Dr. Cucin, quality has never been a metric, but a mindset. His philosophy is simple: “If you prioritize quality, everything else follows”. He firmly believes that optimizing patient outcomes and experiences begins with eliminating anything that doesn’t contribute to safety or measurable clinical improvements. Following this tone, the company focuses on meaningful outcomes, continuous refinement in tools and protocols, and allowing word-of-mouth and data-driven transparency to speak for itself. “Document and Publish your outcomes, and patients will find you,” he emphasizes.
This commitment to quality has been tested and proven over time. During the 2008 recession, subcontractors were struggling to deliver cannulas with the required precision tolerances. Instead of compromising, BioSculpture Tech redesigned the cannulas, moving from a bayonet-style actuation to a concentric configuration that allowed for larger tolerances without sacrificing performance. They also decided to shift to work with an OEM capable of manufacturing both cannulas and handpieces in-house. By removing the pressurized gas, it also made the devices more cost-effective and easier to demonstrate.
A Culture of Continuous Learning
BioSculpture Tech’s culture is powered by values of listening, learning, and evolving. The team believes innovation doesn’t stop at in-house development; it extends to the operating room and patient recovery. Dr. Cucin emphasizes the importance of actively monitoring patient outcomes, keeping feedback channels open with both patients and surgeons, and folding that insight directly into the R&D pipeline. Every comment, concern, or suggestion is a potential catalyst for improvement.
The team actively forges robust connections within the broader medical ecosystem, allowing them to remain at the forefront of industry advancements. By participating in trade shows and continuously scanning for the latest innovations, they cultivate a culture of inherent curiosity and learning. This proactive mindset positions BioSculpture Tech to anticipate and effectively meet the evolving needs of the future.
Dr. Robert L. Cucin: A Healing hand with a visionary Mind
As accomplished as Dr. Cucin is in the operating room, he leads BioSculpture Technology with the same level of surgical precision. His career was shaped by revered mentors such as Dr. Elliot Hochstein at Cornell Med, who instilled in him a simple yet transformative lesson: “Listen to the patient,” as history is as major feature of disease diagnosis as observing signs and symptoms, but also the person behind them to understand their history in context. This philosophy has deeply influenced his leadership, anchoring BioSculpture’s innovations around the real-world needs of both patients and surgeons.
Under Dr. Cucin’s guidance, the company has consistently pursued impact over mere development. Whether it is redesigning cannulas for enhanced patient tolerance or eliminating outdated components to elevate safety and usability, his guidance strikes a remarkable balance between clinical excellence and human-centered care. It ensures every solution is as thoughtful as it is effective.
Carving a legacy for healthier future
With over two decades at the helm, BioSculpture Tech is a key player in the field of obesity-related surgical devices. For Dr. Robert Cucin, the journey has been nothing short of transformational, turning a dinner-table sketch into an FDA-cleared surgical solution. To be involved in every phase of innovation, he went on to learn SolidWorks for engineering design, write motion control software, and navigate regulatory pathways.
The spirit of this innovation continues to push the company forward. Looking ahead, the company is set to unveil its groundbreaking treatments in a rapid roll out through specialized Centers of Excellence. These hubs will serve as training grounds for surgeons, arenas for refining devices through real-world applications, and environments where patients can access cutting-edge, cost-effective care. In this transformative journey, Dr. Cucin envisions BioSculpture Tech reshaping the future of obesity and metabolic disease treatment with more customized innovations.
BioSculpture Technology, Inc. on Social Media
Business Talk is a digital business magazine that caters to CEOs, Entrepreneurs, VC, and Corporates. While working with entrepreneurs and business executives, we focus not only on their achievements. Our mission is to shed light on business entities, including their innovations, technological benchmarks, USPs, and milestones/accolades.
